Global Wealth Management Investment Advisory’s Matinas BioPharma MTNB Stock Holding History

Global Wealth Management Investment Advisory’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-13	Closed	-$141	–	326
2023 Q4	$141	Hold	13	–	–	﹤0.01%	463
2023 Q3	$85	Hold	13	–	–	﹤0.01%	469
2023 Q2	$234	Buy	+13	New	+$303	﹤0.01%	456
2022 Q3	–	Sell	-13	Closed	-$1K	–	348
2022 Q2	$1K	Hold	13	–	–	﹤0.01%	464
2022 Q1	$1K	Hold	13	–	–	﹤0.01%	461
2021 Q4	$1K	Hold	13	–	–	﹤0.01%	427
2021 Q3	$1K	Hold	13	–	–	﹤0.01%	444
2021 Q2	$1K	Hold	13	–	–	﹤0.01%	418
2021 Q1	$1K	Buy	+13	New	+$872	﹤0.01%	442

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Global Wealth Management Investment Advisory's MTNB Position: Q1 2024 in Review

Global Wealth Management Investment Advisory sold out of Matinas BioPharma (MTNB) in Q1 2024, closing a stake of 13 shares — an estimated $141 sold.

Global Wealth Management Investment Advisory first reported a position in MTNB in Q1 2021 and held it in 9 quarters. The position peaked at $1K in Q2 2022. 42 funds tracked by Wall St. Rank hold MTNB as of Q1 2024.

Global Wealth Management Investment Advisory reported no remaining Matinas BioPharma position as of Q1 2024 after selling out during the quarter.
Global Wealth Management Investment Advisory sold 13 Matinas BioPharma shares in Q1 2024, an estimated $141.
Global Wealth Management Investment Advisory first reported a position in Matinas BioPharma in Q1 2021 and held it in 9 quarters.
Global Wealth Management Investment Advisory's Matinas BioPharma position peaked at $1K in Q2 2022.
42 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2024.

Based on Global Wealth Management Investment Advisory's 13F filing for Q1 2024, filed 10 May 2024.